Novartis plans to give away world's costliest therapy to some patients
Updated : December 20, 2019 02:30 PM IST
Zolgensma, with sales of $175 million through September, won US approval in May and has been touted as potentially curative for babies treated before symptoms begin.
The programme applies to countries where the medicine is not yet approved for the rare genetic disorder affecting 1 in 10,000 live births.
Roche's programme for risdiplam, the price of which has not been disclosed, would initially target patients with type 1 SMA, the most severe form.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more